Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

2.875 +0.375 (+15.00%)
Streaming Delayed Price Updated: 10:04 AM EDT, May 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
Replimune Group: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
Barclays Maintains Overweight Rating for Replimune Group: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? ↗
Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was... 
Via Benzinga
News headline image
J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024 ↗
REPL stock results show that Replimune Group missed analyst estimates for earnings per share the fourth quarter of 2024. 
Via InvestorPlace
News headline image
Crude Oil Moves Lower; AutoZone Profit Tops Views ↗
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&P 500... 
Via Benzinga
Topics Stocks
News headline image
The Latest Analyst Ratings for Replimune Group ↗
 
Via Benzinga
News headline image
Analyst Ratings for Replimune Group ↗
 
Via Benzinga
Replimune Group Inc. (NASDAQ: REPL) Making Surprising Moves in Monday Session
Via Investor Brand Network
News headline image
Recap: Replimune Group Q4 Earnings ↗
 
Via Benzinga
News headline image
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Falls 100 Points; ISM Services PMI Increases In November ↗
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday. The Dow traded down 0.28% to 36,103.52 while the NASDAQ rose 0.32% to 14,230.64. The S&P... 
Via Benzinga
Topics Stocks
News headline image
Why Is Replimune (REPL) Stock Down 48% Today? ↗
Replimune stock is dropping on Tuesday as investors in REPL shares react to a clinical trial missing both of its primary endpoints. 
Via InvestorPlace
News headline image
US Stocks Down; JM Smucker Posts Upbeat Earnings ↗
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.23% to 36,120.88 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
News headline image
What's Going On With Cancer-Focused Replimune Stock Today? ↗
Replimune Group Inc (NASDAQ: REPL) announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for locally advanced or metastatic cutaneous  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
From Incyte
Via Business Wire
News headline image
Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review ↗
The Nasdaq held near 52-week highs while small caps ramped up. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes ↗
ImmunoGen and Day One gained Monday on their updates at a cancer treatment conference. 
Via Investor's Business Daily
News headline image
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding. 
Via Benzinga
News headline image
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform ↗
Last Thursday, Replimune Group Inc (NASDAQ: REPL) announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗
 
Via Benzinga
News headline image
PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday ↗
 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.